fasudil has been researched along with Cold Fingers, Hereditary in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fava, A | 1 |
| Wung, PK | 1 |
| Wigley, FM | 1 |
| Hummers, LK | 1 |
| Daya, NR | 1 |
| Ghazarian, SR | 1 |
| Boin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.[NCT03211325] | 29 participants (Actual) | Interventional | 2016-10-18 | Completed | |||
| Development of an Application for the Monitoring and Evaluation of Raynaud's Phenomenon[NCT03984422] | 120 participants (Anticipated) | Observational | 2020-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fasudil and Cold Fingers, Hereditary
| Article | Year |
|---|---|
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Adult; Aged; Cross-Over Studies | 2012 |